Nature Communications

OCT 24, 2026 · JOURNAL ARTICLE

Coordinated regulation of nuclear integrity and STING trafficking by miR-30d suppresses innate immunity in breast cancer

Nature Communications

Immune evasion is a key driver of tumour evolution and a major barrier to effective cancer therapy, frequently arising through suppression of the cytosolic DNA-sensing cGAS–STING p

OCT 23, 2026 · JOURNAL ARTICLE

Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial

Nature Communications

Abstract Severe immune-related adverse events (irAE) in cancer patients receiving immune checkpoint inhibitors (ICI) require treatment interruption and immunosuppression. Based on

OCT 23, 2026 · JOURNAL ARTICLE

Signaling by RasG12V requires EGFR function in vivo to trigger full downstream pathway activation

Nature Communications

Abstract Ras proteins regulate signaling pathways initiated by tyrosine kinase receptors, and activating Ras mutations are drivers in cancer and RASophaties. The development of the

OCT 23, 2026 · JOURNAL ARTICLE

Suppressor tRNAs restore functionally enhanced tumour suppressor protein to induce tumour regression

Nature Communications

Abstract Nonsense mutations in tumour suppressor genes (TSGs) drive cancer initiation and progression but remain “undruggable” due to formidable challenges in rescuing the function

OCT 21, 2026 · JOURNAL ARTICLE

Longitudinal ctDNA profiling reveals genomic risk and molecular response to bireociclib in advanced breast cancer

Nature Communications

Bireociclib plus fulvestrant improves outcomes in hormone receptor-positive, HER2-negative advanced breast cancer, but molecular determinants of benefit and resistance remain uncle

OCT 20, 2026 · JOURNAL ARTICLE

Fatty acids in the tumor microenvironment reprogram neutrophils to induce adenosine-mediated immunosuppression in mice

Nature Communications

As solid tumors progress, the tumor microenvironment becomes increasingly immunosuppressive, impairing cytotoxic T-cell activity and limiting the efficacy of immune checkpoint bloc

OCT 19, 2026 · JOURNAL ARTICLE

A genetic platform to deconvolve efficacy and toxicity reveals the on-target effects of CDK11 inhibition in vivo

Nature Communications

The cyclin-dependent kinase CDK11 is an understudied kinase that has been the subject of conflicting reports regarding its function in cancer. Here, we combine genetic and pharmaco

OCT 19, 2026 · JOURNAL ARTICLE

Near-infrared-responsive thia-hexaphyrin-based covalent organic frameworks for cancer phototherapy

Nature Communications

Abstract Covalent organic frameworks (COF) have emerged as promising phototherapeutic platforms for tumor therapy, where the columnar π-arrayed metal-free photosensitizers serve as